Investment Themes

Investing in Life Sciences: Biotechnology

To access our selection of stocks, regularly updated with new opportunities, discover our customized subscription formulas with exclusive tools.

Investment Themes

For decades, investment in the life sciences sector was mainly channelled through large pharmaceutical companies in oligopolistic or quasi-oligopolistic situations. This began to change in the 1980s with the emergence of new players. Some emerged by taking advantage of structural changes in the sector, such as generic drug manufacturers. Others relied on discovery and innovation to explore new territories. The latter category is now well established in the stock market landscape. These players, commonly referred to as "biotechs", have even become an investment theme in their own right, with their own specificities, codes and unprecedented scale of risk.

Biotechnology... a sector that investors love, even if it often gives them a hard time. In the stock market, investing in a "biotech" is to aspire to the thrill of the clinical success of a slowly maturing treatment. But for a success, how many failures? Investing in a biotech player means accepting a less rational approach to the market. It is also a high-risk gamble that requires strong nerves. At first glance, you even have to be a little reckless to invest in a biotech. It's like investing money with maximum risk in the hope that, after a long and complex process, the company will commercialize a product or technology that will bring in millions or even billions. Currently, about 4 out of 5 drugs in development are derived from biotechnology research, which says a lot about the importance of biotechnology research. On the stock market, the sector is very popular, much like the Internet stocks of the late 1990s. Investors are hoping to make large capital gains, much more than they are likely to get from a player in the traditional economy. But there is always a counterpart with extraordinary potential: it is an extraordinary risk. The following list includes a panel of major players in the sector: it is a list of discovery, not investment. It has been deliberately limited to laboratories whose capitalization is already high, by applying a limit to the number of US stocks, which largely dominate the sector.

Our selection

Healthcare
Other Biotechnology & Medical Research
31.13B +5.81%
Healthcare
Other Biotechnology & Medical Research
7.31B -44.38%
Healthcare
Bio Therapeutic Drugs
22.98B -41.01%
Healthcare
Bio Therapeutic Drugs
8.53B -3.84%
Healthcare
Other Biotechnology & Medical Research
282M -67.42%
Healthcare
Bio Therapeutic Drugs
2.31B -51.70%
Healthcare
Other Biotechnology & Medical Research
213M -56.84%
Healthcare
Other Biotechnology & Medical Research
2.69B -4.95%
Healthcare
Other Biotechnology & Medical Research
355M -11.84%
Healthcare
Bio Diagnostics & Testing
1.27B +56.51%
Healthcare
Bio Therapeutic Drugs
22.35B +22.69%
Healthcare
Bio Therapeutic Drugs
2.58B -46.53%
Healthcare
Bio Therapeutic Drugs
11.47B -14.99%
Healthcare
Other Biotechnology & Medical Research
3.66B +41.70%
Healthcare
Bio Therapeutic Drugs
3.54B -18.94%
Healthcare
Bio Therapeutic Drugs
937M +3.08%
Healthcare
Bio Therapeutic Drugs
58.81B +16.99%
Healthcare
Bio Therapeutic Drugs
1.89B +17.06%
Healthcare
Bio Therapeutic Drugs
5.28B +42.00%
Healthcare
Other Biotechnology & Medical Research
8.97B +62.95%
Healthcare
Bio Therapeutic Drugs
342M -8.68%
Healthcare
Bio Therapeutic Drugs
1.82B +0.87%
Healthcare
Other Biotechnology & Medical Research
52.46M -3.17%
Healthcare
Bio Therapeutic Drugs
854M -14.42%
Healthcare
Bio Therapeutic Drugs
1.19B -38.71%
Healthcare
Bio Therapeutic Drugs
96.34M -39.49%
Healthcare
Other Biotechnology & Medical Research
3.4B -26.88%
Healthcare
Bio Therapeutic Drugs
3.08B +16.35%
Healthcare
Bio Therapeutic Drugs
694M -79.47%
Healthcare
Other Biotechnology & Medical Research
6.63B +26.18%
Healthcare
Other Biotechnology & Medical Research
7.9B -34.72%
Healthcare
Other Biotechnology & Medical Research
345M -1.51%
Healthcare
Other Biotechnology & Medical Research
1.78B -26.65%
Healthcare
Other Biotechnology & Medical Research
984M +21.02%
Healthcare
Bio Therapeutic Drugs
911M -33.77%
Healthcare
Other Biotechnology & Medical Research
1.51B +43.24%
Healthcare
Bio Therapeutic Drugs
2.08B -12.68%
Healthcare
Other Biotechnology & Medical Research
548M -29.88%
Healthcare
Other Biotechnology & Medical Research
1.29B +14.56%
Healthcare
Other Biotechnology & Medical Research
1.93B -5.29%
Healthcare
Bio Therapeutic Drugs
495M -45.56%
Healthcare
Other Biotechnology & Medical Research
197M -68.76%
Healthcare
Bio Therapeutic Drugs
1.43B +1.90%
Healthcare
Other Biotechnology & Medical Research
120M -8.14%
Healthcare
Bio Therapeutic Drugs
2.28B -48.58%
Healthcare
Bio Therapeutic Drugs
81.3M -56.92%
Healthcare
Bio Therapeutic Drugs
98.82M +278.00%
Healthcare
Bio Therapeutic Drugs
789M -24.46%
Healthcare
Bio Therapeutic Drugs
253M -22.83%
Healthcare
Other Biotechnology & Medical Research
154M +45.04%
Healthcare
Bio Therapeutic Drugs
273M +11.31%
Healthcare
Bio Therapeutic Drugs
105M -48.50%
Healthcare
Bio Therapeutic Drugs
445M +78.65%
Healthcare
Other Biotechnology & Medical Research
524M +73.22%
- - 55.91M -
Healthcare
Other Biotechnology & Medical Research
57.23M -58.52%
Healthcare
Other Biotechnology & Medical Research
1.84B +49.24%
Healthcare
Bio Therapeutic Drugs
152M -20.92%
Healthcare
Other Biotechnology & Medical Research
152M -5.05%
Healthcare
Other Biotechnology & Medical Research
102M -27.94%

News of the components

░░░░ ░░░░░░░░ ░░░░░░ ░░░░░░░░░ ░░░░░░░░ ░░░░░ ░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░ ░░░ ░░░░░░ ░░░░░░ ░░░░░░░░░░░░ ░░ ░░░░░░ ░░░░ ░░░░░░░░░░ ░░ ░░░░░░░ ░░░ ░░░░ ░ ░░░░░░░░░░░░
░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░ ░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░ ░░░░░ ░░░░░░░ ░░░░░ ░░ ░░░░░ ░░ ░░░░░░░░ ░░░░░ ░░░░░░░░░░ ░░░░░░░░░░░ ░░ ░░░░░░░░ ░░░░ ░░░░░░░░░░░ ░░░░░░░ ░░░░░░░░ ░░░ ░░░░░ ░░░░░░░░░░░░░░░
░░░░ ░░░░░░░░░░░ ░░░░░░░ ░░ ░░░ ░░░░░░░░░░░░░ ░░░░░░░ ░░░░░░░ ░░ ░░░░░░ ░░░ ░░░░░░░░░ ░░░░░ ░░ ░░░░░░░░░░ ░░░░░ ░░░░░ ░░ ░░░░░ ░░░░░░░░░░░
░░░░ ░░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░
░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░ ░░░░░░ ░░░░░░ ░░░ ░░░░░ ░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░ ░░░░ ░░░░░░░░ ░░ ░░░░ ░░░░░░░░ ░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░ ░░░░░░ ░░░ ░░░░░░░ ░░░░░░░░░░░ ░░░░ ░░ ░░░░░░░░░░░░
░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░░░ ░░░ ░░ ░░░░░░░ ░░░░░░ ░░░░░ ░░░░░░ ░░ ░░░ ░░░░░░░░░
░░░░ ░░░░ ░░░░░░░░ ░░░░░░ ░░░░░ ░░░░░░ ░░░ ░░░░░░ ░░ ░░░ ░░░░░ ░░░░░░░░ ░░░░░░░░░░ ░░░░░░░
░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░
░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░
░░░░ ░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░░ ░░ ░░░░░░░░░░ ░░░░░░░░░░░░ ░░ ░░░░░ ░░░░░░ ░░░░░░░ ░░░░░░░░
░░░░ ░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░ ░░ ░░░░░ ░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░░
░░░░ ░░░░░░░░░░░░ ░░ ░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░ ░░░░░░░░░░░ ░░ ░░░ ░░░░░░░ ░░ ░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░ ░░░░░░ ░░░░░░ ░░░░ ░░░░░░░ ░░░░ ░░░░░░░░░░░░
░░░░ ░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░ ░░░░░ ░░░░░░░░ ░░░░░ ░░░░ ░░░░░░░░░░░░ ░░░░░ ░░░░░░ ░░░░░░░ ░░░░ ░░░░░░░░░░░░
░░░░ ░░░░░ ░░ ░░░░░░░ ░░░░░░ ░░░░░░ ░░░░░ ░░░ ░░░░░░ ░░ ░░░░░ ░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░░░ ░░░░░░░
░░░░ ░░░░░░░ ░░░░░░░░░░ ░░ ░░░░░░░ ░░ ░░ ░░░░░ ░░░░ ░░░░░░ ░░░░ ░░░░░░░░░
░░░░ ░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░ ░░ ░░░ ░░░░░░░ ░░ ░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░ ░░░░░░ ░░░░░░ ░░░░ ░░░░░░░ ░░░░ ░░░░░░░░░░░░
░░░░ ░░░░░░ ░░░░░ ░░░░░ ░░ ░░░░░░░░ ░░░░ ░░░░░░░░░░░░ ░░░░░ ░░░░░░ ░░░░░░░ ░░░░░░░░

Heatmap

Sector allocation

Ratings chart - Surperformance

Ratings ESG MSCI

  1. Stock Market
  2. Investment Themes
  3. Investing in Life Sciences: Biotechnology